Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model

ABSTRACT: Analyses of differential gene expression analyses from intact versus castrated Nkx3.1CE2/+ or Nkx3.1CE2/+; Ptenf/f mice

ORGANISM(S): Mus musculus

PROVIDER: GSE39054 | GEO | 2012/07/04

SECONDARY ACCESSION(S): PRJNA169930

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model

Project description:Analyses of differential gene expression analyses from intact versus castrated Nkx3.1CE2/+ or Nkx3.1CE2/+; Ptenf/f mice Total RNA isolated form phenotypically wild-type (intact) Nkx3.1CE2/+ (n = 3), intact Nkx3.1CE2/+; Ptenf/f (n = 6), and castrated Nkx3.1CE2/+; Ptenf/f (n = 6) prostate. Please contact Cory Abate-Shen (cabateshen@columbia.edu) for questions about the submission.

2012-07-03 | E-GEOD-39054 | biostudies-arrayexpress

Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.

Project description: Not available

| S-EPMC3432676 | biostudies-literature

Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.

Project description: Not available

| S-EPMC2881502 | biostudies-other

Preclinical Evaluation of Dual mTOR inhibitor, AZD2014, and Castration in Prostate Cancer

Project description:Purpose: RNA sequence analysis identified active proliferation of T cells in the combination therapy Methods: Pten-null tumours were collected 4 hours after the last dose (18th day). Total RNA from tumor samples was isolated using the Allprep kit (Qiagen, Germany). The quantity of the RNA was assessed by Qubit (Life technologies) and quality was measured by Bioanalyzer 2100 (Agilent). Samples with 8 or more RNA integrity number (RIN) were used for library preparation and subsequent RNA sequencing. Library preparation was carried out using the Illumina® TruSeq Stranded mRNA Library Preparation Kit (Life Technologies) according to manufacturer recommendations. Single-end 50 bp sequencing reads were generated using Illumina HiSeq and were aligned to the human genome version hg19 or the mouse genome version mm10 using TopHat v2.0.4. Normalisation of read counts and identification of differential expression of genes (DEGs) were carried out using the DESeq v1.10.1 work flow. Results: RNA sequence analysis identified differential gene expression between treatment groups and combination therapy clearly demonstrated active proliferation of cytotoxic lymphocytes. Conclusions: Our study represents the first detailed analysis of Pten-null transcriptomes, with biologic replicates, generated by RNA-seq technology. The optimized data analysis workflows reported here should provide a framework for comparative investigations of expression profiles. Our results show that NGS offers a comprehensive and more accurate quantitative and qualitative evaluation of mRNA content within a cell or tissue. We conclude that RNA-seq based transcriptome characterization would expedite genetic network analyses and permit the dissection of complex biologic functions.

2020-01-21 | GSE93897 | GEO

Schlafen family member 5 (SLFN5) regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer (PART 2)

Project description:Androgen-deprivation therapy (ADT) is the standard of care for the treatment of non-resectable prostate cancer (PCa). Despite high treatment efficiency, most patients ultimately develop lethal castration-resistant prostate cancer (CRPC). In this study, we perform a comparative proteomic analysis of three in vivo, androgen receptor (AR)–driven, orthograft models of CRPC. Differential proteomic analysis reveals that distinct molecular mechanisms, including amino acid (AA) and fatty acid (FA) metabolism, are involved in the response to ADT between the different models. Despite this heterogeneity, we identify SLFN5 as an AR-regulated biomarker in CRPC. SLFN5 expression is high in CRPC tumours and correlates with poor patient outcome. In vivo, SLFN5 depletion strongly impairs tumour growth in castrated condition. Mechanistically, SLFN5 interacts with ATF4 and regulates the expression of LAT1, an essential AA transporter. Consequently, SLFN5 depletion in CRPC cells decreases intracellular levels of essential AA and impairs mTORC1 signalling in a LAT1-dependent manner.

2022-10-14 | PXD021405 | Pride

Schlafen family member 5 (SLFN5) regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer (PART 1)

2022-04-06 | PXD021428 | Pride

Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.

Project description: Not available

| S-EPMC6597087 | biostudies-literature

Novel nanococktail of a dual PI3K/mTOR inhibitor and cabazitaxel for castration-resistant prostate cancer.

Project description: Not available

| S-EPMC7567330 | biostudies-literature

Omipalisib Inhibits Esophageal Cancer Growth through PI3K/AKT/mTOR Signalling Pathway Disruption

Project description:Esophageal squamous cell carcinoma (OSCC) is a lethal digestive tract malignancy with limited effective interventions. This study aims to explore a new potential inhibitor on OSCC and investigate the underlying mechanisms. Based on a drug screen of an FDA-proven library consisting of 1404 compounds, we demonstrated that Omipalisib, a dual PI3K/mTOR inhibitor, markedly inhibited cell proliferation and colony formation in a panel of OSCC cell lines. Mechanistically, Omipalisib induced G0/G1 phase cell cycle arrest and apoptosis. Moreover, RNA-seq, KEGG and GSEA confirmed that the PI3K/mTOR signalling pathway is the primary target of Omipalisib in OSCC cells. Omipalisib treatment suppressed the PI3K/mTOR signalling pathway. Furthermore, Omipalisib exerted a significant antineoplastic effect on OSCC tumour xenografts in BALB/c nude mice without obvious side effects. The present study supports the rationale for using Omipalisib as a therapeutic approach for OSCC cases and suggests the potential clinical evaluation of this strategy.

2020-01-11 | GSE143462 | GEO

8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma.

Project description: Not available

| S-EPMC3031409 | biostudies-literature